# Patent

## Title
Tetracyclic spirobenzazepine dopamine antagonists

## Abstract

The compounds according to the present invention exhibit a strong affinity to the .sigma.-receptor and are useful as psychopharmaceuticals.

## Background
1. Field of the Invention

The present invention relates to a condensed heterocyclic compound and a psychopharmaceutical composition containing the same.

The condensed heterocyclic compounds and salts thereof according to the present invention show activities specific to the .sigma.-receptor, and therefore, are effective as remedies for treating psychoneurosis.

2. Description of the Related Art

The principal conventionally developed remedies for treating psychosis are D.sub.2 -receptor antagonists such as butyrophenone derivatives represented by Haloperidol, phenothiazine, and thioxanthine, owing to the presence of dopamine in the brain.

Nevertheless, many cases have been known which cannot be improved by the use of these D.sub.2 -receptor antagonists, and it is known that the use thereof is accompanied by side-effects such as extrapyramidal tract disorders. Accordingly, there is a need for the development of a specific remedy for treating psychosis, which is not accompanied by side-effects.

In this connection, it recently has been proved that the .sigma.-receptor, which is a subtype of the opioid receptor, is closely involved in the development of various symptoms of psychosis, and remedies have been developed for treating psychosis based on the .sigma.-receptor antagonism, as represented by Rimcazole and BMY 14802 having the following structures, respectively. ##STR3##

Nevertheless, the antipsychotic effect of these Rimicazole and BMY 14802 is inferior to those of existing remedies such as Haloperidol, and as a cause thereof, it is considered that the .sigma.-receptor antagonism thereof is inferior to those of existing remedies such as Haloperidol.

Accordingly, the objects of the present invention are to eliminate the above-mentioned disadvantages of the prior art and to provide a novel compound having a strong affinity to the .sigma.-receptor and a low affinity to the D.sub.2 -receptor and a psychopharmaceutical composition containing the same.

Other objects and advantages of the present invention will be apparent from the following description.

In accordance with the present invention, there is provided a condensed heterocyclic compound having the formula (I): ##STR4## wherein A and B are both carbonyl groups or one thereof represents a methylene group and the other represents a carbonyl group; Z represents an oxygen atom, a sulfur atom, an unsubstituted or substituted imino group, or a methylene group; n is an integer ranging from 2 to 6; and R represents a group having the following formula: ##STR5## wherein R.sup.1 represents a hydrogen atom or a hydroxyl group; R.sup.2 represents a substituted or unsubstituted phenyl or 2-pyridyl group or salts thereof as well as a psychotropic drug containing the same as an effective component.

In accordance with the present invention, there is also provided a psychopharmaceutical composition comprising the above-mentioned a condensed heterocyclic compound having the formula (I) or a pharmacologically acceptable salt thereof, as an effective component, and a carrier therefor.

The present inventors conducted intensive studies into the developing of a pharmaceutically active compound having a stronger affinity for the .sigma.-receptor and a lower affinity for the D.sub.2 -receptor, and thus a higher selectivity to the .sigma.-receptor, and as a result, found that the compounds having the above-mentioned formula (I) and salts thereof show a strong affinity for the .sigma.-receptor and a low affinity for the D.sub.2 -receptor, and thus completed the present invention.

The typical examples of the substituent in the substituted imino group in the formula (I) of the compounds according to the present inventions are C.sub.1-5 alkyl group (for example, methyl, ethyl, propyl, butyl and pentyl group), aryl group (for example, phenyl, benzyl and phenethyl group) and heterocyclic group (for example, pyridyl group).

The preferable compound (I) according to the present invention are 4-(4-(4-phenyl)-1-piperidnyl) butyl-2,3,4,5-tetrahydro-1,4-benzodiazepine-3,5-dione (A,B=carbonyl group, Z=imino group, n=4, R=piperidinyl group, R.sup.1 =hydrogen atom, R.sup.2 =phenyl group), 4-(5-(4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-5 -one (A=carbonyl group, B=methylene group, Z=oxygen atom, n=5, R=piperidinyl group, R.sup.1 =hydrogen atom, R.sup.2 =phenyl group) and 2-(5-(4-(chlorophenyl)-1-piperidinyl)pentyl-1,3,4,5-tetrahydro-2-benzazepi ne-1,3-dione (A,B=carbonyl group, Z=methylen group, n=5, R=piperidinyl group, R.sup.1 =hydrogen atom, R.sup.2 =4-chlorophenyl group).

The compounds having the above-mentioned formula (I) according to the present invention can be prepared, for example, by the following methods:

1) Preparation of Intermediate Compounds (II): ##STR6## wherein A, B, Z and n are the same as defined above and X and Y may be the same or different and each represents a halogen atom.

2) Preparation of Final Compounds:

(wherein R is the same as defined above).

More specifically, a compound represented by the following general formula (Ia): ##STR7## i.e., a compound of the formula (I), wherein A is a carbonyl group, B is a methylene group and Z is an oxygen atom, can be prepared by forming a compound having the following formula (III): ##STR8## according to the method disclosed in the article of G. S. Sidhu, G. Thyagarajan and U. T. Bhalerao (J. Chem. Soc. (C), 1966, p. 969), reacting same with a dibromoalkane to form a compound having the formula (IV): ##STR9## and then condensing the resulting compound with an amine derivative of the formula (V) in the usual manner.

A compound having the following general formula (Ib): ##STR10## i.e., a compound of the formula (I) wherein A is a methylene group, B is a carbonyl group and Z is an oxygen atom, can be prepared by forming a compound having the following formula (VI): ##STR11## according to the method disclosed in the article of Kost. A. N., Stankevicius, A. (Khim. Geterotsiki. Soedin., 1971, 7 (9), p. 1288), reacting it with a dibromoalkane to give a compound having the following general formula (VII) ##STR12## and then condensing the resulting compound with an amine derivative (V) in a usual manner. A compound having the following general formula (Ic): ##STR13## i.e., a compound of the formula (I) wherein A and B each represents a carbonyl group and Z is an oxygen atom, can be prepared by forming a compound having the following formula (VIII): ##STR14## according to the method disclosed in the article of A. Cattaneo, P. Galimberti, M. Melandri (Boll. Chim. Farm., 1963, 102, p. 541), reacting it with a dibromoalkane to give a compound having the following general formula (IX) ##STR15## and then condensing the resulting compound with an amine derivative (V) in a usual manner.

The compound having the general formula (I) and pharmacologically acceptable salts thereof (such as hydrochlorides, sulfates, nitrates, hydrobromides, phosphates, methanesulfonates, p-toluenesulfonates, acetates, oxalates, malonates, succinates, tartrates, maleates, fumarates, lactates, citrates and malates) according to the present invention can be administered alone, or if necessary and desirable, in combination with other commonly pharmacologically acceptable additives such as carriers, excipients and diluents in desired shapes such as tablets, capsules, powder, liquids, injectable liquids, and suppositories through oral or parenteral routes. Examples of such carriers or diluents are polyvinylpyrrolidone, gum arabic, gelatin, sorbit, cyclodextrin, tragacanth, magnesium stearate, talc, polyethylene glycol, polyvinyl alcohol, silica, lactose, crystalline cellulose, sugar, starches, potassium phosphate, vegetable oils, calcium carboxymethyl cellulose, sodium laurylsulfate, water, ethanol, glycerin, mannitol, and syrup.

The concentration of the compound of the formula (I) in the pharmaceutical composition is not restricted, but is generally from 1 to 100% by weight, preferably 10 to 90% by weight. Moreover, the dose thereof is not critical, but is generally from 0.01 to 1,000 mg/day/man, preferably 0.1 to 500 mg/day/man. The frequency of the administration is usually 1 to 3 times per day.

The present invention will now be further illustrated by, but is by no means limited to, the following Reference Examples, Examples and Test Examples. 4-(5-bromopentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-5-one ##STR16##

In 20 ml of dimethylformamide (DMF) was dissolved 100 mg of 2,3,4,5-tetrahydro-1,4-benzoxazepin-5-one, and the solution then ice-cooled. Then, to the resulting solution were added 0.251 ml (3 equivalents) of 1,5-dibromopentane and 29.4 mg (1.2 equivalent) of a 60% sodium hydride oil dispersion, and the mixture was stirred for one hour with ice-cooling. The reaction solution was poured into a citric acid aqueous solution and extracted with ethyl acetate, and the ethyl acetate phase was washed with an aqueous saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and then filtered. The filtrate was then concentrated and the resulting residue was purified by silica gel column chromatography (eluent: hexane/ethyl acetate (8:2)) to give 124 mg (yield: 65.0%) of the title compound. 4-(5-bromopentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-3-one ##STR17##

In 20 ml of DMF was dissolved 100 mg of 2,3,4,5-tetrahydro-1,4-benzoxazepin-3-one and the solution then ice-cooled. Then, to the resulting solution were added 0.125 ml (1.5 equivalent) of 1,5-dibromopentane and 29.4 mg (1.2 equivalent) of a 60% sodium hydride oil dispersion and the mixture was stirred for 1.5 hour with ice-cooling. Thereafter, the reaction solution was reacted and/or treated and purified in the same manner as in Reference Example 1 to give 133 mg (yield: 69.5%) of the title compound. 4-(5-bromopentyl)-2,3,4,5-tetrahydro-1,4-benzothiazepine-3,5-dione ##STR18##

In 20 ml of DMF was dissolved 102 mg of 2,3,4,5-tetrahydro-1,4-benzothiazepine-3,5-dione and the solution then ice-cooled. Then, to the resulting solution were added 0.116 ml (1.5 equivalent) of 1,5-dibromopentane and 27.4 mg (1.2 equivalent) of a 60% sodium hydride oil dispersion and the mixture was stirred for 2 hours with ice-cooling. Thereafter, the reaction solution was reacted and/or treated and purified in the same manner as in Reference Example 1 to give 79.2 mg (yield: 42.4%) of the title compound. 4-(5-bromopentyl)-2,3,4,5-tetrahydro-1,4-benzodiazepine-3,5-dione ##STR19##

In 10 ml of dimethylformamide (DMF) was dissolved 100 mg of 2,3,4,5-tetrahydro-1,4-benzodiazepine-3,5-dione and the solution then ice-cooled. Then, to the resulting solution were added 0.116 ml (1.5 equivalent) of 1,5-dibromopentane and 27.3 mg (1.2 equivalent) of a 60% sodium hydride oil dispersion and the mixture was stirred for 2 hours with ice-cooling. The reaction solution was poured into ice-cooled water containing citric acid, made alkaline with sodium hydrogen carbonate, and extracted with ethyl acetate. The ethyl acetate phase was then washed with an aqueous saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The product was purified in the same manner as in Reference Example 1 to give 97.5 mg (yield: 52.8%) of the title compound. 2-(5-bromopentyl)-1,3,4,5-tetrahydro-2-benzazepine-1,3-dione ##STR20##

In 20 ml of DMF was dissolved 100 mg of 1,3,4,5-tetrahydro-2-benzazepine-1,3-dione and the solution then ice-cooled. Then, to the resulting solution were added 0.117 ml (1.5 equivalent) of 1,5-dibromopentane and 27.4 mg (1.2 equivalent) of a 60% sodium hydride oil dispersion and the mixture was stirred for 1.5 hour with ice-cooling. Thereafter, the reaction solution was reacted and/or treated and purified in the same manner as in Reference Example 1 to give 109 mg (yield: 58.9%) of the title compound.

Physical data of the compounds prepared in Reference Examples 1 to 5 are summarized in Table 1. __________________________________________________________________________ Ref. Ex. No. m.p. IR (cm.sup.-1) NMR (.delta. ppm)    Mass __________________________________________________________________________ 1      Oily 2930 2870 1.48-1.96(m, 6H)     HiMs product 1640 1600 3.43(t, 2H, J=6.6Hz), 3.50(t, 2H, J=5.3Hz) Calcd. 311.0520 1470 1420 3.60-3.65(m. 2H)     Obsd. 311.0504 1360 1320 4.37(t, 2H, J=5.3Hz) 1285 1210 7.00(d. 1H, J=7.9Hz) 1110 1045 7.16(t, 1H, J=7.9Hz) 875 805 7.41(dt, 1H, J=2.0Hz & 7.9Hz) 790 760 7.80(dd, 1H, J=2.0Hz & 7.9Hz) 705 2      Oily 2930 2870 1.38-1.92(m, 6H)     HiMs product 1670 1640 3.37(t, 2H, J=6.6Hz) Calcd. 311.0520 1580 1495 3.55(t, 2H, J=7.3Hz) Obsd. 311.0536 1460 1435 4.47(s, 2H) 1350 1310 4.69(s, 2H) 1230 1220 7.03-7.33(m, 4H) 1195 1115 1055 1025 845 760 700 3      Oily 2920 2850 1.43-1.95(m, 6H)     HiMs product 1690 1640 3.40(t, 2H, J=6.6Hz) Calcd. 341.0084 1580 1455 3.68(s, 2H)          Obsd. 341.0074 1430 1330 4.00(t, 2H, J=7.3Hz) 1290 1260 7.37-7.49(m, 3H) 1220 1105 8.16-8.20(m, 1H) 1080 950 910 780 740 685 4      65-66.degree. C. 3350 2940 1.39-1.92(m, 6H)     HiMs 2860 1700 3.78(t, 2H, J=6.6Hz) Calcd. 324.0472 1620 1495 3.87-3.92(m, 2H)     Obsd. 324.0424 1430 1395 3.90(d, 2H, J=4.6Hz)4.87(t, 1H, J=4.6Hz) 1360 1320 6.79(d. 1H, J=7.9Hz) 1240 1155 6.95(dd, 1H, J=7.3Hz & 7.9Hz) 1125 1105 7.35(ddd, 1H, J=1.3Hz & 7.3Hz & 7.9Hz) 1020 980 8.25(dd, 1H, J=1.3Hz & 7.9Hz) 860 785 755 700 5      Oily 2950 2860 1.48-1.97(m, 6H)     HiMs product 1700 1645 2.99(s, 4H)          Calcd. 323.0520 1600 1455 3.40-3.45(m, 2H)     Obsd. 323.0472 1340 1315 4.00(t, 2H, J=7.3Hz) 1265 1240 7.16(d, 1H, J=7.3Hz) 1210 1115 7.33-7.48(m, 2H) 1040 890 7.96(dd, 1H, J=1.3Hz & 7.9Hz) 795 755 710 __________________________________________________________________________ 4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-5-one ##STR21##

The same procedures as used in Reference Example 1 were repeated except that 1,4-dibromobutane was substituted for 1,5-dibromopentane to give the title compound. 4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-3-one ##STR22##

The same procedures as used in Reference Example 2 were repeated except that 1,4-dibromobutane was substituted for 1,5-dibromopentane to give the title compound. 4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-3,5-dione ##STR23##

The same procedures as used in Reference Example 1 were repeated except that 2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was substituted for 2,3,4,5-tetrahydro-1,4-benzoxazepin-3-one to give the title compound. 4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzothiazepine-3,5-dione ##STR24##

The same procedures as used in Reference Example 3 were repeated except that 1,4-dibromobutane was substituted for 1,5-dibromopentane to give the title compound. 4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzothiazepine-3,5-dione ##STR25##

The same procedures as used in Reference Example 4 were repeated except that 1,4-dibromobutane was substituted for 1,5-dibromopentane to give the title compound. 1-methyl-4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzothiazepine-3,5-dione ##STR26##

The same procedures as used in Reference Example 10 were repeated except that 1-methyl-2,3,4,5-tetrahydro-1,4-benzodiazepine-3,5-dione was substituted for 2,3,4,5-tetrahydro-1,4-benzothiazepine-3,5-dione to give the title compound. 2-(4-bromobutyl)-1,3,4,5-tetrahydro-2-benzazepine-1,3-dione ##STR27##

The same procedures as used in Reference Example 5 were repeated except that 1,4-dibromobutane was substituted for 1,5-dibromopentane to give the title compound. 4-(5-bromopentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione ##STR28##

The same procedures as used in Reference Example 8 were repeated except that 1,5-dibromopentane was substituted for 1,4-dibromobutane to give the title compound. 4-(4-(4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-5- one ##STR29##

In 10 ml of dioxane was dissolved 49.8 mg of the compound obtained in Reference Example 6, 80.8 mg (3 equivalents) of 4-phenylpiperidine was added to the resulting solution, and the mixture was stirred at 110.degree. C. for 3 hours with heating. The dioxane was distilled off, an aqueous solution of sodium hydrogen carbonate was added thereto, and the resulting solution was extracted with methylene chloride. The methylene chloride phase was washed with water, dried over anhydrous magnesium sulfate, and then filtered. The resulting filtrate was concentrated and the residue obtained was subjected to silica gel column chromatography (developing solution : ethyl acetate) to give 56.3 mg (yield: 89.1%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-(4-chlorophenyl)-1-piperidinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzo xazepin-5-one ##STR30##

In 110 ml of dioxane was dissolved 61.3 mg of the compound prepared in Reference Example 6, then 121 mg (3 equivalents) of 4-(4-chlorophenyl)piperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 3 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 76.9 mg (yield: 90.6%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-hydroxy-4-phenyl)-1-piperidinyl)butyl)-2,3,4,5-tetrahydro-1,4-benz oxazepin-5-one ##STR31##

In 10 ml of dioxane was dissolved 119 mg of the compound prepared in Reference Example 6, then 212 mg (3 equivalents) of 4-hydroxy-4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 100.degree. C. for 2 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 153 mg (yield: 97.2%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-phenyl)-1-piperidinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-5 -one ##STR32##

In 10 m l of dioxane was dissolved 20 mg of the compound prepared in Reference Example 7, then 32.5 mg (3 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 100.degree. C. for 5 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 17.9 mg (yield: 70.5%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-chlorophenyl)-1-piperidinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxaz epin-3-one ##STR33##

In 7 ml of dioxane 30.5 mg of the compound prepared in Reference Example 7, then 60 mg (3 equivalents) of 4-(4-chlorophenyl)piperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 4 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 21.7 mg (yield: 51.4%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-hydroxy-4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzo xazepin-3-one ##STR34##

In 10 ml of dioxane was dissolved 45.0 mg of the compound prepared in Reference Example 7, then 80.3 mg (3 equivalents) of 4-hydroxy-4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 4 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 58.3 mg (yield: 98.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-(4-chlorophenyl)-4-hydroxy)-1-piperidinyl)-butyl-2,3,4,5-tetrahydr o-1,4-benzoxazepin-3-one ##STR35##

In 8 ml of dioxane was dissolved 47.0 mg of the compound prepared in Reference Example 7, then 100 mg (3 equivalents) of 4-(4-chlorophenyl)-4-hydroxypiperidine was added thereto, and the resulting mixture was stirred at 120.degree. C. for 3 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 61.2 mg (yield: 90.5%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3 ,5-dione ##STR36##

In 40 ml of dioxane was dissolved 1.30 g of the compound prepared in the Reference Example 8, 966 mg (1.5 equivalent) of 4-phenylpiperidine and 1.10 g (2 equivalents) of anhydrous potassium carbonate were added to the resulting solution, and the mixture was refluxed for 16 hours. The dioxane was distilled off under a reduced pressure, water and ethyl acetate were added to the resulting residue to perform a liquid-liquid separation, the ethyl acetate phase was dried over anhydrous magnesium sulfate, and then the solvent was distilled off under a reduced pressure. The residue was developed with ethyl acetate-hexane (9:1) using silica gel column chromatography to give 1.52 g (yield: 96.8%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-(4-chlorophenyl)-1-piperidinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzo xazepine-3,5-dione ##STR37##

In 8 ml of dioxane was dissolved 20 mg of the compound prepared in Reference Example 8, then 37.6 mg (3 equivalents) of 4-(4-chlorophenyl)piperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 6 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 19.1 mg (yield: 69.7%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-hydroxy-4-phenyl)-1-piperidinyl)butyl)-2,3,4,5-tetrahydro-1,4-benz oxazepine-3,5-dione ##STR38##

In 10 ml of dioxane was dissolved 114 mg of the compound prepared in Reference Example 8, then 194 mg (3 equivalents) of 4-hydroxy-4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 120.degree. C. for 3 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 148 mg (yield: 99.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-(4-chlorophenyl)-4-hydroxy-l-piperidinyl)butyl-2,3,4,5-tetrahydro- 1,4-benzoxazepine-3,5-dione ##STR39##

In 10 ml of dioxane was dissolved 48.7 mg of the compound prepared in Reference Example 8, then 99.0 mg (3 equivalents) of 4-(4-chlorophenyl)-4-hydroxypiperidine was added thereto, and the resulting mixture was stirred at 120.degree. C. for 6 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 58.0 mg (yield: 83.9%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-phenyl-1,2,3,6-tetrahydro)-1-pyridyl)butyl-2,3,4,5-tetrahydro-1,4- benzoxazepine-3,5-dione ##STR40##

In 10 ml of dioxane was dissolved 218 mg of the compound prepared in Reference Example 8, then 318 mg (2.9 equivalents) of 4-phenyl-1,2,3,6-tetrahydropyridine was added thereto, and the resulting mixture was refluxed for 20 hours. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 50 mg (yield: 18.2%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-(4-chlorophenyl)-1,2,3,6-tetrahydro-1-pyridyl)butyl-2,3,4,5-tetrah ydro-1,4-benzoxazepine-3,5-dione ##STR41##

In 10 ml of dioxane was dissolved 50 mg of the compound prepared in Reference Example 8, then 93.0 mg (3 equivalents) of 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 7 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 23.0 mg (yield: 33.7%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-(2-pyridyl)-1-piperidinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazep ine-3,5-dione ##STR42##

In 20 ml of dioxane was dissolved 326 mg of the compound obtained in Reference Example 8, 552 mg (2 equivalents) of 4-(2-pyridyl)piperidine.trifluoroacetate and 2.76 g (20 equivalents) of anhydrous potassium carbonate were added thereto, and the resulting mixture was refluxed for 8 hours. The dioxane was distilled off under a reduced pressure, a 0.5 N aqueous solution of sodium hydroxide was added to the resulting residue, the product was extracted with ethyl acetate, the ethyl acetate phase was dried over anhydrous magnesium sulfate, and then the solvent was distilled off under a reduced pressure. The residue obtained was subjected to silica gel column chromatography (developing solution: methylene chloride-methanol (9:1) to give 270 mg (yield: 68.5%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from ethanol-ether. 4-(4-(4-hydroxy-4-(2-pyridyl)-1-piperidinyl)butyl)-2,3,4,5-tetrahydro-1,4- benzoxazepine-3,5-dione ##STR43##

In 20 ml of dioxane was dissolved 326 mg of the compound obtained in Reference Example 8, 873 mg (3 equivalents) of 4-hydroxy-4-(2-pyridyl)piperidine.trifluoroacetate and 2.76 g (20 equivalents) of anhydrous potassium carbonate were added thereto, and the resulting mixture was refluxed for 3 days. The same procedures for reaction and treatment as used in Example 8 were repeated and the resulting residue was subjected to silica gel column chromatography (developing solution: methylene chloride-methanol (10:1)) to give 270 mg (yield: 66.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from ethanol-ether. 4-(4-(4-(2-pyridyl)-1,2,3,6-tetrahydro-1-pyridyl)butyl)-2,3,4,5-tetrahydro -1,4-benzoxazepine-3,5-dione ##STR44##

In 20 ml of dioxane was dissolved 260 mg of the compound obtained in Reference Example 8, 411 mg (1.9 equivalent) of 4-(2-pyridyl)-1,2,3,6-tetrahydropyridine.trifluoroacetate and 2.07 g (19 equivalents) of anhydrous potassium carbonate were added thereto, and the resulting mixture was refluxed for 23 hours. The dioxane was distilled off under a reduced pressure, ethyl acetate and conc. aqueous ammonia were added to the resulting residue to separate into solutions, the ethyl acetate phase was dried over anhydrous magnesium sulfate, and then the solvent was distilled off under a reduced pressure. The residue obtained was purified in the same manner as used in Example 8 to give 179 mg (yield: 57.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from ethanol-ether. 4-(4-(4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzothiazepine -3,5-dione ##STR45##

In 5 ml of dioxane was dissolved 27.0 mg of the compound prepared in Reference Example 9, then 41.5 mg (3 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 3.5 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 15.7 mg (yield: 46.3%) of the title compound. The maleate of this compound was obtained by converting the compound into maleate in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro- 1,4-benzodiazepine-3,5-dione ##STR46##

In 5ml of dioxane was dissolved 16.3 mg of the compound prepared in Reference Example 10, then 25.4 mg (3 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 4 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 16.9 mg (yield: 62.2%) of the title compound. The hydrochloride and fumarate of this compound were obtained by converting the compound into hydrochloride and fumarate in the usual manner, and then recrystallizing the salts from methylene chloride-ether. 4-(4-(4-chlorophenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzothia zepine-3,5-dione ##STR47##

In 10 ml of dioxane was dissolved 33.0 mg of the compound prepared in Reference Example 10, then 31.1 mg (1.5 equivalent) of 4-(4-chlorophenyl)piperidine and 22.0 mg (1.5 equivalent) of potassium carbonate were added thereto, and the resulting mixture was stirred at 110.degree. C. for 21 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 29.3 mg (yield: 65.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(4-(4-hydroxy-4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzo diazepine-3,5-dione ##STR48##

In 10 ml of dioxane was dissolved 44.8 mg of the compound prepared in Reference Example 10, then 76.5 mg (3 equivalents) of 4-hydroxy-4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 100.degree. C. for 4 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 51.7 mg (yield: 88.2%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. -1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzodiazepine-3,5-dione ##STR49##

In 10 ml of dioxane was dissolved 56.9 mg of the compound prepared in Reference Example 11, then 62.0 mg (2.2 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 12 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 66.6 mg (yield: 93.9%) of the title compound. The fumarate of this compound was obtained by converting the compound into fumarate in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 2-(4-(4-phenyl)-1-piperidinyl)butyl-1,3,4,5-tetrahydro-2-benzazepine-1,3-d ione ##STR50##

In 5 ml of dioxane was dissolved 19.7 mg of the compound prepared in Reference Example 12, then 30.7 mg (3 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 4 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 21.9 mg (yield: 88.3%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 2-(4-(4-(4-chlorophenyl)-1-piperidinyl)butyl)-1,3,4,5-tetrahydro-2-benzaze pine-1,3-dione ##STR51##

In 10 ml of dioxane was dissolved 20.0 mg of the compound prepared in Reference Example 12, then 18.9 mg (1.5 equivalents) of 4-(4-chlorophenyl)piperidine and 13.3 mg (1.5 equivalent) of potassium carbonate were added thereto, and the resulting mixture was stirred at 110.degree. C. for 21 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 19.9 mg (yield: 72.5%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 2-(4-(4-phenyl)-1-piperidinyl)butyl-1,3,4,5-tetrahydro-2-benzazepine-1,3-d ione ##STR52##

In 10ml of dioxane was dissolved 53.5 mg of the compound prepared in Reference Example 12, then 91.8 mg (3 equivalents) of 4-hydroxy-4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 4 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 68.6 mg (yield: 98.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 2-(4-(4-(4-chlorophenyl)-4-hydroxy)-1-piperidinyl)butyl-1,3,4,5-tetrahydro -2-benzazepine-1,3-dione ##STR53##

In 10 ml of dioxane was dissolved 39.0 mg of the compound prepared in Reference Example 12, then 79.8 mg (3 equivalents) of 4-(4-chlorophenyl)-4-hydroxypiperidine was added thereto, and the resulting mixture was stirred at 120.degree. C. for 5 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 52.0 mg (yield: 93.8%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(5-(4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-5 -one ##STR54##

In 10 ml of dioxane was dissolved 80.0 mg of the compound prepared in Reference Example 1, then 95 mg (2.2 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 100.degree. C. for 6 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 94.8 mg (yield: 93.4%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(5-(4-(4-chlorochenyl)1-piperidinyl)pentyl)-2,3,4,5-tetrahydro-1,4-benzo xazepin-5-one ##STR55##

In 10 ml of dioxane was dissolved 64.5 mg of the compound prepared in Reference Example 1, then 116 mg (3 equivalents) of 4-(4-chlorophenyl)piperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 6 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 86.3 mg (yield: 99.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(5-(4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-3 -one ##STR56##

In 10 ml of dioxane was dissolved 65.0 mg of the compound prepared in Reference Example 2, then 96.0 mg (3 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 8 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 49.0 mg (yield: 60.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(5-(4-(4-chlorophenyl)1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzox azepin-3-one ##STR57##

In 10 ml of dioxane was dissolved 65.2 mg of the compound prepared in Reference Example 2, then 123 mg (3 equivalents) of 4-(4-chlorophenyl)piperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 6 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 46.7 mg (yield: 52.4%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(5-(4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzoxazepine- 3,5-dione ##STR58##

In 10 ml of dioxane was dissolved 40.0 mg of the compound prepared in Reference Example 13, then 62.0 mg (3 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 100.degree. C. for 3  hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 39.8 mg (yield: 79.2%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(5-(4-(4-chlorophenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzo xazepine-3,5-dione ##STR59##

In 20 ml of dioxane was dissolved 100 mg of the compound prepared in Reference Example 13, then 173 mg (3 equivalents) of 4-(4-chlorophenyl)piperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 7 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 123 mg (yield: 92.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 4-(5-(4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzothiazepin e-3,5-dione ##STR60##

In 5 ml of dioxane was dissolved 30.5 mg of the compound prepared in Reference Example 3, then 29.0 mg (2.2 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 24 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 33.4 mg (yield: 88.0%) of the title compound. The maleate and fumarate of this compound was obtained by converting the compound into maleate and fumarate in the usual manner, and then fumarate was recrystallized from ether-hexane. 4-(5-(4-(4-phenyl)-1-piperidinyl)pentyl)-2,3,4,5-tetrahydro-1,4-benzothiaz epine-3,5-dione ##STR61##

In 10 ml of dioxane was dissolved 44.0 mg of the compound prepared in Reference Example 3, then 57.7 mg (2.2 equivalents) of 4-(4-chlorophenyl)piperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 30 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 37.5 mg (yield: 63.1%) of the title compound. The maleate of this compound was obtained by converting the compound into maleate in the usual manner. 4-(5-(4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzodiazepine -3,5-dione ##STR62##

In 5 ml of dioxane was dissolved 57.8 mg of the compound prepared in Reference Example 4, then 86.0 mg (3 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 100.degree. C. for 8 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 70.8 mg (yield: 98.3%) of the title compound. The fumarate of this compound was obtained by converting the compound into fumarate in the usual manner, and then recrystallizing the salt from acetone-ether. 4-(5-(4-(4-chlorophenyl)-1-piperidinyl)pentyl)-2,3,4,5-tetrahydro-1,4-benz odiazepine-3,5-dione ##STR63##

In 5 ml of dioxane was dissolved 40.9 mg of the compound prepared in Reference Example 4, then 61.5 mg (2.5 equivalents) of 4-(4-chlorophenyl)piperidine was added thereto, and the resulting mixture was stirred at 100.degree. C. for 12 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 49.9 mg (yield: 90.2%) of the title compound. The fumarate of this compound was obtained by converting the compound into fumarate in the usual manner, and then recrystallizing the salt from acetone-ether. 2-(5-(4-phenyl)-1-piperidinyl)pentyl-1,3,4,5-tetrahydro-2-benzazepine-1,3- dione ##STR64##

In 8 ml of dioxane was dissolved 44.0 mg of the compound prepared in Reference Example 5, then 48.2 mg (2.2 equivalents) of 4-phenylpiperidine was added thereto, and the resulting mixture was stirred at 110.degree. C for 6 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 46.6 mg (yield: 85.0%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether. 2-(5-(4-(4-chlorophenyl)-1-piperidinyl)pentyl)-1,3,4,5-tetrahydro-2-benzaz epine-1,3-dione ##STR65##

In 10 ml of dioxane was dissolved 61.2 mg of the compound prepared in Reference Example 5, then 111 mg (3 equivalents) of 4-(4-chlorophenyl)piperidine was added thereto, and the resulting mixture was stirred at 110.degree. C. for 7 hours with heating. Thereafter, the same procedures for reaction, treatment and purification as used in Example 1 were repeated to give 66.7 mg (yield: 79.6%) of the title compound. The hydrochloride of this compound was obtained by converting the compound into hydrochloride in the usual manner, and then recrystallizing the salt from methylene chloride-ether.

The physical data of the compounds prepared in Examples 1 to 37 are summarized in Table II. __________________________________________________________________________ Ex. No. m.p.    IR (cm.sup.-1) NMR (.delta.ppm)      Elemental Analysis __________________________________________________________________________ 1   202-205.degree. C. 2920 2750 1.59-1.78(m, 6H), 1.82-1.86(m, 2H) HCl salt 1/4 H.sub.2 O (HCl salt) 1630 1600 2.02-2.09(m, 2H), 2.42-2.54(m, 3H) C  H  N 1465 1450 3.05-3.09(m, 2H), 3.51(t, 2H, J=5.3Hz) Calc. 68.72 7.57 6.68 1410 1360 3.62-3.67(m, 2H), 4.38(t, 2H, J=5.3Hz) Obsd. 68.98 7.53 6.74 1280 1205 7.00(d, 1H, J=7.9Hz) 1100 1040 7.16-7.32(m, 6H) 800 755 7.40(ddd, 1H, J=1.3Hz&7.3Hz&7.9Hz) 695  7.80(dd, 1H, J=1.3Hz&7.9Hz) 2   205-207.degree. C. 2920 2740 1.57-1.81(m, 8H), 1.96-2.06(m, 2H) HCl salt 3/4 H.sub.2 O (HCl salt) 1635 1600 2.38-2.50(m, 3H), 3.00-3.04(m, 2H) C  H  N 1465 1410 3.46(t, 2H, J=5.3Hz)  Calc. 62.26 6.86 6.05 1370 1310 3.58- 3.63(m, 2H)     Obsd. 62.12 6.56 6.02 1280 1205 4.34(t, 2H, J=5.3Hz) 1105 1080 6.97(d, 1H, J=7.9Hz) 1040 1005 7.09-7.40(m, 6H) 820 800 7.77(dd, 1H, J=1.3Hz&7.9Hz) 755 695 3   192-194.degree. C. 3350 2930 1.50-1.82(m, 6H), 2.23-2.38(m, 2H) HCl salt 1/4 H.sub.2 O (HCl salt) 2820 1625 2.55-2.68(m, 4H)          C  H  N 1470 1420 3.51(t, 2H, J=5.3Hz)  Calc. 66.19 7.29 6.43 1380 1305 3.66(t, 2H, J=6.6Hz)  Obsd. 66.08 7.42 6.42 1280 1210 4.38(t, 2H, J=5.3Hz)7.00(d, 1H, J=8.6Hz) 1120 1040 7.16(dd, 1H, J=7.3Hz&7.9Hz) 980 800 7.30-7.44(m, 4H) 760 730 7.52(d, 2H, J=7.3Hz) 695  7.79(dd, 1H, J=1.3Hz&7.3Hz) 4   189-190.degree. C. 2920 2750 1.44-1.59(m, 4H), 1.71-1.78(m, 4H) HCl salt 1/4 H.sub.2 O (HCl salt) 1660 1630 1.93-2.02(m, 2H), 2.31-2.45(m, 3H) C H  N 1570 1485 2.93-2.97(m, 2H), 3.48-3.53(m, 2H) Calc. 68.72 7.57 6.68 1470 1430 4.43(s, 2H), 4.62(s, 2H) Obsd. 68.71 7.44 6.71 1340 1300 6.95-7.00(m, 2H) 1220 1185 7.09-7.25(m, 7H) 1115 1050 1015 750 690 5   167-169.degree. C. 2920 2750 1.48-1.64(m, 4H), 1.72-1.80(m, 4H) HCl salt (HCl salt) 1660 1575 1.97-2.04(m, 2H), 2.36-2.49(m, 3H) C  H  N 1485 1450 2.97-3.02(m, 2H), 3.52-3.57(m, 2H) Calc. 64.14 6.73 6.23 1340 1300 4.47(s, 2H)           Obsd. 64.00 7.02 6.15 1220 1190 4.67(s, 2H) 1120 1090 6.99-7.25(m, 8H) 1050 1010 820 755 690 6   176-179.degree. C. 3350 2920 1.56-1.81(m, 6H), 2.32-2.34(m, 2H) HCl salt 1/2 H.sub.2 O (HCl salt) 2810 1650 2.57-2.65(m, 4H), 2.90-2.94(m, 2H) C  H  N 1570 1485 3.59(t, 2H), J= 6.6Hz) Calc. 65.51 7.33 6.37 1440 1345 4.51(s, 2H), 4.70(s, 2H) 65.80 7.38 6.43 1300 1220 7.02-7.07(m, 2H) 1185 1125 7.18-7.53(m, 7H) 1040 1020 755 695 7   182-184.degree. C. 3350 2920 1.48-1.74(m, 6H)      HCl salt (HCl salt) 2800 1640 2.09-2.20(m, 2H)          C  H  N 1485 1460 2.39-2.50(m, 4H)      Calc. 61.93 6.50 6.02 1430 1360 2.78-2.82(m, 2H)      Obsd. 61.66 6.45 5.98 1300 1220 3.55-3.60(m, 2H) 1190 1125 4.50(s, 2H), 4.70(s, 2H) 1090 1040 7.02-7.46(m, 8H) 1010 910 820 755 730 695 8   174-176.degree. C. 2940 2800 1.52-1.83(m, 8H),     HCl salt 3/4 H.sub.2 O (HCl salt) 2770 1705 2.04(m, 2H)               C  H  N 1650 1600 2.40(t, 2H, J=7.3Hz)  Calc. 65.15 6.94 6.33 1490 1460 2.48(m, 1H), 3.04(d, 2H, J=11.2Hz) Obsd. 65.00 6.56 6.25 1290 1210 4.02(t, 2H, J=7.9Hz), 4.75(s, 2H) 1110 1060 7.08(dd, 1H, J=1.3Hz&7.9Hz) 1040 760 7.15-7.31(m, 6H) 700  7.51(m, 1H) 8.16(dd, 1H, J=1.3Hz&7.9Hz) 9   202-204.degree. C. 2910 2750 1.55-1.83(m, 8H), 1.98-2.08(m, 2H) HCl salt (HCl salt) 1700 1645 2.38-2.51(m, 3H)          C  H  N 1600 1480 3.02-3.07(m, 2H), 4.01(t, 2H, J=7.3Hz) Calc. 62.20 6.09 6.05 1440 1360 4.75(s, 2H), 7.08-7.30(m, 6H) Obsd. 62.51 6.36 5.96 1330 1290 7.51(ddd, 1H, J=1.3Hz&7.9Hz&8.6Hz) 1210 1120 8.17(dd, 1H, J=1.3Hz&7.9Hz) 1080 1005 815 780 760 690 10   151-153.degree. C. 3350 2930 1.47-1.79(m, 6H)      HCl salt 1/4 H.sub.2 O (HCl salt) 2800 1700 2.14-2.25(m, 2H), 2.41-2.51(m, 4H) C  H  N 1640 1600 2.64-2.88(m, 2H)      Calc. 64.13 6.62 6.23 1480 1445 3.99-4.05(m, 2H)      Obsd. 64.32 6.77 6.26 1360 1335 4.76(s, 2H) 1290 1215 7.10(d, 1H, J=7.9Hz) 1040 955 7.21-7.55(m, 7H) 815 755 8.17(dd, 1H, J=1.7Hz&7.9Hz) 695 11   186-188.degree. C. 3300 2900 1.44-1.75(m, 6H),     HCl salt (HCl salt) 2750 1695 2.05-2.20(m, 2H)          C  H  N 1640 1600 2.35-2.55(m, 4H)      Calc. 60.13 5.89 5.84 1475 1445 2.78-2.90(m, 2H), 3.98-4.03(m, 2H) Obsd. 59.98 5.82 5.79 1360 1330 4.76(s, 2H) 1285 1205 7.08(d, 1H, J=7.9Hz) 1115 1080 7.21-7.54(m, 6H) 1035 820 8.15(dd, 1H, J=1.3Hz&7.9Hz) 760 12   141-145.degree. C. 2550 1710 1.60-1.78(m, 4H)      Mass (HCl salt) 1640 1480 2.50(t, 2H), J=7.9Hz), 2.57(m, 2H) HiMs (free base) 1450 1300 2.70(t, 2H, J=5.3Hz), 3.14(m, 2H) Calc. 390.1942 1220 1120 4.03(t, 2H, J=7.9Hz), 4.75(s, 2H) Obsd. 390.1943 6.05(m, 1H), 7.09(dd, 1H, J=1.3Hz&7.9Hz) 7.20-7.40(m, 6H) 7.51(m, 1H) 8.16(dd, 1H, J=1.3Hz&7.9Hz) 13   155-158.degree. C. 2880 2750 1.49-1.70(m, 4H)      HCl salt 1/4 H.sub.2 O (HCl salt) 1700 1640 2.41-2.45(m, 4H), 2.61-2.65(m, 2H) C  H  N 1600 1480 3.06-3.08(m, 2H), 3.92-3.98(m, 2H) Calc. 60.30 5.89 5.84 1440 1335 4.68(s, 2H), 5.96-5.98(m, 2H) Obsd. 60.03 5.66 5.87 1290 1215 7.02(d, 1H, J=7.9Hz) 1120 1090 7.14-7.47(m, 6H) 1040 820 8.09(dd, 1H, J=1.3Hz&8.4Hz) 760 14   167-170.degree. C. 2940 1705 1.57-2.12(m, 10H),    Mass (HCl salt) 1650 1600 2.42(t, 2H, J=7.3Hz), 2.71(m, 1H) HiMs (free base) 1480 1460 3.06(d, 2H, J=11.9Hz), 4.02(t, 2H, J=7.9Hz) Calc. 393.2051 1440 1300 4.76(s, 2H), 7.09(dd, 1H, J=1.3Hz, &7.9Hz) Obsd. 393.2057 1220 1130 7.12-7.23(m, 3H), 7.51(m, 1H) 1040 760 7.61(m, 1H), 8.16(dd, 1H, J=1.3Hz&7.9Hz) 8.51(dd, 1H, J=1.3Hz&4.0Hz) 15   188-190.degree. C. 3300 2950 1.56-1.77(m, 6H), 1.94(br, s, 1H) Mass (HCl salt) 2820 1705 2.11(dt, 2H, J=4.6Hz&12.5Hz) HiMs (free base) 1650 1600 2.47-2.57(m, 4H), 2.88(m, 2H) Calc. 409.2000 1490 1460 4.02(t, 2H, J=7.9Hz), 4.76(s, 2H) Obsd. 409.2004 1440 1300 7.09(dd, 1H, J=1.3Hz&7.9Hz) 1220 1130 7.18-7.24(m, 2H), 7.40(d, 1H, J=7.9Hz) 1050 790 7.51(m, 1H), 7.71(m, 1H) 8.16(dd, 1H, J=1.3Hz&7.9Hz) 8.51(d, 1H, J=4.6Hz) 16   172-175.degree. C. 2920 2800 1.55-1.75(m, 4H), 2.52(t, 2H, J=7.9Hz) Mass (HCl salt) 1700 1650 2.65-2.75(m, 4H), 3.22(m, 2H) HiMs (free base) 1600 1580 4.03(t, 2H, J=7.3Hz), 4.75(s, 2H) Calc. 391.1893 1480 1460 6.62(s, 1H), 7.07-7.14(m, 2H) Obsd. 391.1881 1450 1430 7.23(m, 1H), 7.36(d, 1H, J=8.6Hz) 1370 1290 7.51(m, 1H), 7.62(m, 1H) 1220 1120 8.16(dd, 1H, J=1.3Hz&7.9Hz) 1040 760 8.55(d, 1H, J=4.0Hz) 17   103-105.degree. C. 2920 2750 1.51-1.83(m, 8H)      Maleate (Maleate) 1695 1635 1.98-2.07(m, 2H)           C H  N 1580 1440 2.37-2.50(m, 3H), 3.01-3.06(m, 2H) Calc. 64.10 6.15 5.34 1430 1350 3.68(s, 2H), 4.03(t, 2H, J=7.2Hz) Obsd. 63.76 6.35 5.22 1320 1265 7.16-7.49(m, 8H) 1110 1085 8.17-8.21(m, 1H) 780 740 695 18   153-155.degree. C. 3250 2920 1.40-1.63(m, 4H), 1.66-1.75(m, 4H) HCl salt H.sub.2 O (Fumarate) 2850 1685 1.89-1.98(m, 3H), 2.92-2.96(m, 2H) C  H  N 1630 1600 3.83(d, 2H, J=4.6Hz), 3.83-3.89(m, 2H) Calc. 64.63 7.23 9.42 1485 1425 4.77(t, 1H)           Obsd. 64.92 7.09 9.36 1360 1315 6.70(d, 1H, J=7.9Hz) 1285 1150 6.87(dd, 1H, J=7.3Hz&7.9Hz) 1120 1010 7.08-7.30(m, 6H) 970 780 8.18(dd, 1H, J=1.3Hz&7.9Hz) 740 690 19   Undeterminable 3300 2920 1.49-1.81(m, 8H), 1.95-2.04(m, 2H) HCl salt H.sub.2 O because of 2750 1690 2.31-2.49(m, 3H), 2.98-3.03(m, 2H) C  H  N hygroscopicity 1635 1600 3.90(d, 2H, J=4.6Hz), 3.93(t, 2H, J=7.3Hz) Calc. 60.00 6.50 8.75 (HCl salt) 1485 1425 4.91(t, 1H, J=4.6Hz)  Obsd. 59.76 6.70 8.62 1360 1315 6.78(d, 1H, J=7.9Hz) 1290 1120 6.94(dd, 1H, J=7.2Hz&7.9Hz) 1085 1005 7.12-7.37(m, 5H) 970 820 8.25(dd, 1H, J=1.3Hz&7.9Hz) 780 745 695 20   203-205.degree. C. 3300 2930 1.41-1.76(m, 6H), 2.10-2.22(m, 2H) HCl salt 1/2 H.sub.2 O (HCl salt) 2800 1685 2.38-2.46(m, 4H), 2.78-2.82(m, 2H) C  H  N 1625 1600 3.91(d, 2H, J=4.6Hz), 3.49(t, 2H, J=6.6Hz) Calc. 63.63 6.90 9.28 1480 1420 4.75(t, 1H, J=4.6Hz)  Obsd. 63.21 6.79 9.18 1360 1315 6.78(d, 1H, J=7.9Hz) 1290 1120 6.95(dd, 1H, J=7.3Hz&8.6Hz), 1035 970 7.23-7.38(m, 4H) 775 745 7.51(d, 2H, J=7.2Hz) 690  8.26(dd, 1H, J=1.3Hz&8.6Hz), 21   153-155.degree. C. 2910 2750 1.51-1.81(m, 6H)      Fumarate 1/2 H.sub.2 O (Fumarate) 1690 1630 1.95-2.07(m, 2H), 2.37(t, 2H, J=7.2Hz) C  H  N 1595 1490 2.37-2.53(m, 1H), 2.98-3.02 (m, 2H) Calc. 65.64 6.84 7.92 1430 1360 3.22(s, 3H), 3.85(s, 2H) Obsd. 65.49 6.88 7.94 1325 1260 3.89-3.94(m, 2H) 1240 1190 6.91-6.98(m, 2H) 1100 1070 7.18-7.46(m, 6H) 995 775 8.32(d, 1H, J=7.9Hz) 745 695 22   175-177.degree. C. 2920 2730 1.47-1.78(m, 8H)      HCl salt 1/2 H.sub.2 O (HCl salt) 1690 1635 1.92-2.02(m, 2H), 2.32-2.43(m, 3H) C  H  N 1595 1485 2.92(s, 4H), 2.92-3.01(m, 2H) Calc. 68.87 7.40 6.43 1440 1305 3.93-3.98(m, 2H)      Obsd. 69.13 7.23 6.43 1265 1180 7.08-7.37(m, 8H) 1100 745 7.89(dd, 1H, J=1.3Hz&7.9Hz) 690 23   180-182.degree. C. 2920 2750 1.55-1.81(m, 8H)      HCl salt (HCl salt) 1690 1640 1.99-2.08(m, 2H), 2.39-2.50(m, 3H) C  H  N 1595 1490 2.99-3.07(m, 6H)      Calc. 65.07 6.55 6.07 1440 1370 3.99-4.05(m, 2H)      Obsd. 65.01 6.62 6.14 1335 1310 7.13-7.47(m, 7H) 1270 1180 7.96(dd, 1H, J=1.3Hz&7.9Hz) 1100 1005 885 820 750 710 24   201-202.degree. C. 3350 2930 1.52-1.79(m, 6H)      HCl salt 1/4 H.sub.2 O (HCl salt) 2800 1690 2.14-2.25(m, 2H), 2.41-2.51(m, 4H) C  H  N 1640 1600 2.83-2.88(m, 2H), 3.00(s, 4H) Calc. 67.10 7.10 6.26 1490 1440 4.00-4.05(m, 2H)      Obsd. 67.22 7.07 6.27 1380 1300 7.17(d, 1H, J=7.3Hz) 1265 1180 7.25-7.54(m, 7H) 1105 1040 7.96(d, 1H, J=7.9Hz) 960 790 755 695 25   186-188.degree. C. 3400 2920 1.49-1.75(m, 6H)      HCl salt (HCl salt) 2800 1690 2.09-2.20(m, 2H), 2.40-2.48(m, 4H) C  H  N 1640 1600 2.84-2.96(m, 2H), 2.99(s, 4H) Calc. 62.89 6.33 5.87 1480 1440 4.03(t, 2H, J=7.3Hz)  Obsd. 62.39 6.25 5.82 1340 1315 7.16(d, 1H, J=7.3Hz) 1270 1185 7.29-7.46(m, 6H) 1110 1040 7.96(d, 1H, J=7.9Hz) 1010 960 820 790 750 26   178-180.degree. C. 3300 2920 1.39-1.72(m, 6H), 1.83-1.90(m, 4H) HCl salt 1/2 H.sub.2 O (HCl salt) 2860 2750 2.06-2.15(m, 2H), 2.39-2.55(m, 3H) C  H  N 1630 1600 3.07-3.15(m, 2H)      Calc. 68.55 7.82 6.40 1460 1420 3.50(t, 2H, J=5.3Hz)  Obsd. 69.00 7.65 6.41 1370 1315 3.60-3.65(m, 2H), 4.38(t, 2H, J=5.3Hz) 1280 1210 7.00(d, 1H, J=8.7Hz) 1105 1040 7.12-7.43(m, 7H), 980 800 7.80(dd, 1H ,J=2.0Hz&7.9Hz) 755 695 27   180-181.degree. C. 2900 2740 1.33-1.52(m, 2H), 1.53-1.88(m, 8H) HCl salt (HCl salt) 1635 1600 2.02-2.10(m, 2H), 2.36-2.54(m, 3H) C  H  N 1460 1410 3.06-3.10(m, 2H)      Calc. 64.79 6.96 6.04 1360 1310 3.50(t, 2H, J=5.3Hz), 3.62(t, 2H, J=7.2Hz) Obsd. 64.64 6.93 6.03 1280 1205 4.38(t, 2H, J=5.3Hz), 7.00(d, 1H, J=7.9Hz) 1085 1040 7.13-7.27(m, 5H), 820 755 7.40(dt, 1H, J=1.3Hz&7.9Hz) 690  7.81(dd, 1H, J=1.3Hz&7.9Hz) 28   161-163.degree. C. 2920 2730 1.26-1.40(m, 2H), 1.49-1.70(m, 4H) HCl salt 1/4 H.sub.2 O (HCl salt) 1660 1630 1.78-1.89(m, 4H), 2.00-2.10(m, 2H) C  H  N 1485 1450 2.33-2.39(m, 2H)      Calc. 69.27 7.79 6.46 1340 1300 2.47-2.53(m, 1H)      Obsd. 69.30 7.61 6.49 1220 1185 3.02-3.10(m, 2H) 1105 1050 3.55(t, 2H, J=7.3Hz), 4.49(s, 2H) 1020 750 4.69(s, 2H), 7.03-7.32 (m, 9H) 695 29   144-148.degree. C. 2900 2850 1.25-1.36(m, 2H), 1.49-1.69(m, 4H) HCl salt 1/2 H.sub. 2 O (HCl salt) 2750 1660 1.70-1.82(m, 4H), 1.97-2.09(m, 2H) C  H  N 1575 1480 2.32-2.37(m, 2H)      Calc. 63.56 7.04 5.93 1440 1340 2.41-2.51(m, 1H), 3.03-3.07(m, 2H) Obsd. 63.38 6.86 5.91 1300 1215 3.52-3.58(m, 2H) 1185 1080 4.49(s, 2H), 4.69(s, 2H) 1045 1020 7.03-7.32(m, 8H), 815 745 690 30   176-178.degree. C. 2920 2750 1.33-1.72(m, 6H)      HCl salt 1/4 H.sub.2 O (HCl salt) 1700 1645 1.74-1.85(m, 4H), 1.98-2.06(m, 2H) C  H  N 1600 1480 2.35-2.40(m, 2H), 2.45-2.51(m, 1H) Calc. 67.10 7.10 6.26 1445 1370 3.03-3.07(m, 2H), 3.96-4.01(m, 2H) Obsd. 67.16 7.09 6.28 1335 1290 4.76(s, 2H) 1215 1115 7.09(d, 1H, J=7.9Hz) 1060 1040 7.16-7.33(m, 6H) 985 815 7.51(dt, 1H, J=1.3Hz&7.9Hz) 755 695 8.17(dd, 1H, J=1.3Hz&7.9Hz) 31   166-168.degree. C. 2910 2740 1.35-1.44(m, 2H)      HCl salt (HCl salt) 1700 1645 1.48-1.83(m, 8H)          C  H  N 1600 1475 1.96-2.05(m, 2H), 2.33-2.39(m, 2H) Calc. 62.89 6.33 5.87 1440 1360 2.42-2.52(m, 1H), 3.02-3.06(m, 2H) Obsd. 63.02 6.32 5.86 1325 1290 3.95-4.01(m, 2H), 4.76(s, 2H) 1210 1115 7.08-7.27(m, 6H), 1085 1035 7.51(dt, 1H, J=1.3Hz&7.9Hz) 815 760 8.16(dt, 1H, J=1.3Hz&7.9Hz) 690 32   124-128.degree. C. 2930 2750 1.31-1.50(m, 2H)      Fumarate 1/2 H.sub.2 O (Fumarate) 1695 1640 1.51-1.84(m, 8H), 1.94-2.07(m, 2H) C  H  N 1580 1490 2.35(t, 2H), J=7.9Hz), 2.45-2.52(m, 1H) Calc. 63.60 6.44 5.12 1430 1350 3.02-3.06(m, 2H)      Obsd. 63.73 6.41 5.11 1320 1255 3.68(s, 2H), 4.00(t, 2H, J=7.9Hz) 1230 1085 7.16-7.47(m, 8H) 985 780 8.17-8.21(m, 1H), 740 695 33   Oily product 2920 2750 1.33-1.47(m, 2H)      Maleate (Maleate) 1690 1630 1.50-1.85(m, 8H), 1.91-2.04(m, 2H) C  H  N 1580 1490 2.35(t, 2H, J=7.3Hz)  Calc. 60.77 5.80 4.89 1460 1430 2.39-2.52(m, 1H), 3.01-3.05(m, 2H) Obsd. 60.26 5.88 4.78 1320 1255 3.68(s, 2H), 3.97-4.02(m, 2H) 1230 1085 7.13-7.49(m, 7H) 1010 985 8.19(dd, 1H, J=1.9Hz&7.9Hz) 820 780 740 685 34   183-184.degree. C. 3250 2900 1.33-1.39(m, 2H), 1.52-1.84(m, 8H) Fumarate 1/2 H.sub.2 O (Fumarate) 2750 1685 1.98-2.07(m, 2H), 2.33-2.38(m, 2H) C  H  N 1630 1600 2.45-2.48(m, 1H), 3.02-3.07(m, 2H) Calc. 65.64 6.84 7.92 1485 1425 3.91(d, 2H, J=4/6Hz), 3.90-3.93(m, 2H) Obsd. 65.24 6.63 7.72 1350 1310 4.71(t, 1H, J=4.6Hz), 6.77(d, 1H, J=7.9Hz) 1290 1230 6.95(t, 1H, J=7.9Hz), 1150 1110 7.19-7.37(m, 6H) 970 745 8.26(dd, 1H, J=1.3Hz&7.9Hz) 690 35    171-173.degree. C. 3250 2900 1.25-1.39(m, 2H), 1.49-1.84(m, 8H) Fumarate (Fumarate) 2750 1695 1.95-2.05(m, 2H), 2.31-2.37(m, 2H) C  H  N 1640 1605 2.37-2.51(m, 1H), 3.01-3.05(m, 2H) Calc. 62.64 6.16 7.56 1490 1430 3.87-3.92(m, 4H)      Obsd. 62.29 6.17 7.56 1360 1320 4.70-4.73(m, 1H), 6.77(d, 1H, J=8.6Hz) 1240 1120 6.94(t, 1H, J=7.9Hz) 1090 980 7.13-7.37(m, 5H) 825 750 8.26(d, 1H, J=7.9Hz) 36   151-152.degree. C. 2920 2750 1.33-1.44(m, 2H), 1.50-1.84(m, 8H) HCl salt 1/4 H.sub.2 O (HCl salt) 1695 1640 1.98-2.07(m, 4H), 2.37(t, 2H, J=7.9Hz) C  H  N 1600 1445 2.43-2.53(m, 1H), 2.99(s, 4H) Calc. 70.10 7.58 6.29 1335 1310 3.03-3.07(m, 2H)      Obsd. 70.26 7.49 6.29 1240 1180 4.00(t, 2H, J=7.3Hz) 1090 980 7.15-7.44(m, 8H) 885 750 7.97(dd, 1H, J=1.3Hz&7.3Hz) 695 37  175-178.degree. C. 2920 2750 1.35-1.44(m, 2H)      HCl salt (HCl salt) 1690 1640 1.53-1.84(m, 8H)          C  H  N 1595 1485 1.97-2.05(m, 2H), 2.34-2.40(m, 2H) Calc. 65.68 6.78 5.89 1440 1335 2.43-2.51(m, 1H), 2.99(s, 4H) Obsd. 65.60 6.95 5.84 1310 1240 3.03-3.07(m, 2H) 1180 1085 3.97-4.02(m, 2H) 1005 980 7.13-7.45(m, 7H) 880 820 7.97(dd, 1H, J=1.3Hz&7.9Hz) 750 705 __________________________________________________________________________

The pharmacological test results will now be explained.

The affinities of the present compounds to the .delta.-receptor were determined according to a method described in the "Molecular Pharmacology," Vol. 32, 772-784 (1987).

That is, 50 mM of a Tris-HCl (pH=7.7) buffer solution was added to all of the cerebra, other than the cerebellum, of Wistar male rats, followed by homogenizing for 30 minutes in a Polytson.sup..RTM. and then centrifugally separating same at 35000 G for 10 minutes. To the resultant precipitate was added the same buffer solution as used above, and the homogenizing and the centrafugalization were repeated. This procedure was repeated once more, and to the final precipitate was added a 50 mM Tris -HCl (pH=8.0) buffer solution and the receptor having a binding capability. In the binding experiments, 3nM [.sup.3 H] propyl-3-(3-hydroxyphenyl) piperidine (i.e., [.sup.3 H]3PPP) was used, and as a non-specific ligand, 1 .mu.M haloperidol was used. After incubation at 25.degree. C. for 90 minutes, the bound ligand was recovered by filtration and the determination was carried out. The filter used was a Whatmen GF/B filter treated with 0.5% polyethylene imine.

All of the present compounds exhibit strong activities on the order of .mu.M or less. The receptor binding capabilities of the typical compounds are shown in Table III. ______________________________________ Affinity to .delta.-Receptor Example No.    IC.sub.50 (nM) ______________________________________ 1             14.2 2             11.7 4             9.22 5             18.7 8             6.61 9             4.73 12             12.1 14             17.8 17             4.00 18             14.1 19             16.1 21             13.7 22             3.74 23             6.40 26             10.9 27             10.6 28             8.02 29             10.3 30             4.73 31             7.82 32             3.95 33             17.6 36             3.62 37             8.91 ______________________________________ Anfoneric Acid

The inhibitory activity against locomotor hyperactivity induced by amfoneric acid of the present compounds were determined according to a method described in the "Journal of Pharmacology & Experimental Therapeuties," Vol. 239, 124-131 (1986) by R. T. Matthews et al.

That is, to a ddy male mouse having a body weight of about 25g, were simultaneously administered amfoneric acid (2.5 mg/kg, subcutaneous administration) and the present compound (intraperitoneal administration), and the amount of movement was determined using an apparatus for determining the amount of movement of a mouse. The amount of movement was determined over 100 minutes, and the test of significance thereof was effected for the total count number for 100 minutes by a Manwhitnee test. The value was indicated as the inhibition rate based, as a control, upon the group to which 2.5 mg/kg of amfoneric acid was subcutaneously administered.

The results are shown in Table IV. ______________________________________ Inhibitory activity against locomotor hyperativity induced by anfoneric acid Inhibition Rate (%) Example No.  (mg/kg Intraperitoneal administration) ______________________________________ 8           73%* (30) 18           90%** (10), 65%* (1) 19           53%* (10) 22           52%* (10) 26           65%** (10) 29           60%** (10) 30           70%* (30) 37           74%* (10) Control BMY14802 51%* (30) ______________________________________ *0.05 > P > 0.01 **0.01 > P > 0.001

To ddy male mice having a body weight of about 25 g was intraperitoneally administered the present compound and the catalepsy was determined after 30, 60, 90, and 120 minutes therefrom. The score of the catalepsy was as follows.

The forelegs of the mouse were placed on an aupper edge of a 5.5 cm height box and the time until the more fulled its forelegs down from the box or the mouse jumped up onto the top of the box was measured and the score was determined based upon the following standard. Score       Condition ______________________________________ 0           15 sec or less 1           more than 15 sec but less than 30 sec 2           more than 30 sec but less than 60 sec 3           more than 60 sec ______________________________________

The results are evaluated based upon the determined score as follows. Evaluation      Score ______________________________________ -               less than 1 +               more than 1 but less than 2 ++              more than 2 but less than 3 ______________________________________

The results of the typical compounds are shown in Table V. ______________________________________ Catalepsy Catalepsy Example No. (mg/kg Intraperitoneal administration) ______________________________________ 8          - (30) 18          - (10) 19          - (20) 21          - (30) 26          - (30) 29          - (30) 30          - (30) 31          - (30) 37          - (30) Control     ++ (0.1) (Haloperidol) ______________________________________

## Claims

1. A compound of the formula (I): ##STR66## wherein A and B are both carbonyl groups or one thereof represents a methylene group and the other represents a carbonyl group; Z represents an oxygen atom, a sulfur atom, an imino group which may be substituted with a lower alkyl group or a methylene group; n is an integer of 2 to 6; and R represents a group having the following formula: ##STR67## wherein R.sup.1 represents a hydrogen atom or a hydroxy group; R.sup.2 represents a phenyl group which may be substituted with halogen atoms, or pyridyl group; or a pharmacologically acceptable salt thereof.

2. A compound as claimed in claim 1, wherein the substituted imino group in Z is a C.sub.1 -C.sub.5 alkylimino group.

3. A compound as claimed in claim 1, wherein A represents a carbonyl group and B represents a carbonyl group or methylene group.

4. A compound as claimed in claim 1, wherein R represents the following formula: ##STR68## wherein X represents a hydrogen atom or a halogen atom.

5. A psychopharmaceutical composition comprising a compound of the formula (I) according to claim 1 or a pharmacologically acceptable salts thereof, as an effective component, and a carrier thereof.

6. A psychopharmaceutical composition as claimed in claim 5, wherein said compound of the formula (I) is at least one compound selected from the group consisting of 4-(4-(4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzodiazepine- 3,5-dione, 4-(5-(4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-5 -one and 2-(5-(4-(chlorophenyl)-1-piperidinyl)pentyl-1,3,4,5-tetrahydro-2-benzazepi ne-1,3-dione.

7. A psychopharmaceutical composition comprising a compound of the formula (I) according to claim 2 or a pharmacologically acceptable salt thereof, as an effective component, and a carrier thereof.

8. A psychopharmaceutical composition comprising a compound of the formula (I) according to claim 3 or a pharmacologically acceptable salt thereof, as an effective component, and a carrier thereof.

9. A psychopharmaceutical composition comprising a compound of the formula (I( according to claim 4 or a pharmacologically acceptable salt thereof, as an effective component, and a carrier thereof.

10. A psychopharmaceutical composition according to claim 7, wherein the compound of the formula (I) is at least one compound selected from the group consisting of 4-(4-(4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzodiazepine- 3,5-dione, 4-(5-4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-5- one and 2-(5-(4-(chlorophenyl)-1-piperidinyl)pentyl-1,3,4,5-tetrahydro-2-benzazepi ne-1,3-dione.

11. A psychopharmaceutical composition according to claim 8, wherein the compound of the formula (I) is at least one compound selected from the group consisting of 4-(4-(4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzodiazepine- 3,5-dione, 4-(5-4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-5- one and 2-(5-(4-(chlorophenyl)-1-piperidinyl)pentyl-1,3,4,5-tetrahydro-2-benzazepi ne-1,3-dione.

12. A psychopharmaceutical composition according to claim 9, wherein the compound of the formula (I) is at least one compound selected from the group consisting of 4-(4-(4-phenyl)-1-piperidinyl)butyl-2,3,4,5-tetrahydro-1,4-benzodiazepine- 3,5-dione, 4-(5-4-phenyl)-1-piperidinyl)pentyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-5- one and 2-(5-(4-(chlorophenyl)-1-piperidinyl)pentyl-1,3,4,5-tetrahydro-2-benzazepi ne-1,3-dione.